No, Riluzole Should Not Be Used for Severe Agitation
Riluzole has no established role in the management of severe agitation and should not be scheduled for this indication. Riluzole is an agent used primarily for amyotrophic lateral sclerosis (ALS) and has no evidence base, mechanism of action, or clinical rationale for treating agitation in any patient population.
The Actual Problem: Levetiracetam-Induced Agitation
Your patient's severe agitation is likely caused by levetiracetam itself, not an indication for additional medication. Levetiracetam is well-documented to cause behavioral adverse events including agitation, aggression, hostility, and irritability in 13.3% of adult patients 1. These behavioral symptoms can be severe enough to require hospitalization (0.8% of treated patients) and frequently lead to treatment discontinuation (1.7% of patients) 1.
Key Clinical Points About Levetiracetam and Agitation:
- Behavioral adverse events occur in over one-third of patients, with agitation being a prominent feature 1
- Onset is typically within the first 4 weeks of treatment or after dose increases 1
- Symptoms can be severe and acute, including aggression requiring immediate intervention 2
- Resolution is rapid (within 1-2 weeks) after dose reduction or discontinuation 1
- Levetiracetam has actually been shown to be ineffective for treating impulsive aggression in controlled trials 3
Recommended Management Algorithm
Step 1: Address the Root Cause
Reduce or discontinue levetiracetam as the primary intervention. The agitation will likely resolve within 1-2 weeks of dose adjustment 1. Consider switching to an alternative antiseizure medication if seizure control requires continuation of therapy.
Step 2: Acute Agitation Management (If Immediate Control Needed)
For severe agitation requiring immediate pharmacologic intervention while addressing the levetiracetam:
First-line options (based on 2025 geriatric guidelines 4):
- Haloperidol (first-generation antipsychotic) - standard reference agent
- Quetiapine - lowest adverse event rate (OR 0.27 vs haloperidol) 4
- Droperidol - emerging evidence for superior efficacy and safety 5
Avoid benzodiazepines, particularly midazolam, which has a 5.25-fold increased risk of adverse events compared to haloperidol in this setting 4.
Step 3: Alternative Antiseizure Medication Selection
If seizure control requires ongoing therapy, consider switching from levetiracetam to:
- Valproate/divalproex - effective for seizures AND has anti-aggressive properties 3
- Phenytoin - Level A recommendation for seizure control 6 and first-line for impulsive aggression 3
- Carbamazepine - effective secondary option for both seizures and aggression 3
Critical Pitfall to Avoid
Do not add more medications to treat a medication-induced adverse effect. The instinct to "treat through" levetiracetam-induced agitation by adding agents like riluzole (which has no role here) or additional sedatives creates polypharmacy risks without addressing the underlying cause. The FDA label explicitly warns about these behavioral effects and notes they resolve with discontinuation 1.
The combination of levetiracetam and phenytoin your patient is already receiving provides no synergistic benefit for the agitation—in fact, levetiracetam is the likely culprit. Address the cause, not the symptom.